Comparative Pharmacology
Head-to-head clinical analysis: ELAPRASE versus NAGLAZYME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELAPRASE versus NAGLAZYME.
ELAPRASE vs NAGLAZYME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Idursulfase is a recombinant form of iduronate-2-sulfatase, the enzyme deficient in Hunter syndrome (MPS II). It hydrolyzes 2-sulfate groups from the terminal iduronate sulfate glycosaminoglycans (GAGs) dermatan sulfate and heparan sulfate, thereby reducing GAG accumulation in tissues.
NAGLAZYME (galsulfase) is a recombinant form of human N-acetylgalactosamine 4-sulfatase that replaces deficient endogenous enzyme in patients with mucopolysaccharidosis VI (MPS VI). It catalyzes the hydrolysis of N-acetylgalactosamine 4-sulfate groups from glycosaminoglycans (GAGs), reducing GAG accumulation in lysosomes.
0.58 mg/kg IV once weekly administered over 1 hour
1 mg/kg intravenously once weekly.
None Documented
None Documented
Terminal half-life: 6.5–8.5 hours (mean 7.5 h) in pediatric patients; supports weekly IV dosing
Terminal elimination half-life: 6-9 minutes (0.1-0.15 hours); clinically, rapid clearance requires weekly intravenous administration to maintain therapeutic levels.
Renal: negligible; primarily catabolized via peptide hydrolysis to amino acids, which are reused or excreted
Renal: 87% of administered dose excreted unchanged in urine within 24 hours; minimal biliary/fecal elimination.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy